Drug intelligence / Profile preview

KJ14004

Development stage: Preclinical
Lead developer: Kukje Pharm
Modality: Small Molecules
Administration: Ophthalmic

Overview

KJ14004 (also known as HCS-001) is a small molecule combination therapy under development by Kukje Pharm for the treatment of ophthalmic diseases, specifically dry eye syndrome. It is classified as an "improved/modified new drug" (IMD) or "incrementally modified drug" (개량신약) in South Korea, a designation typically applied to new combinations, formulations, or strengths of previously approved active ingredients. As of 2024, the program is in the discovery research stage, and the specific active ingredients comprising the combination have not been publicly disclosed.

Beyond the preview

Go deeper on KJ14004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ14004.

Explore the full profile